{
    "nctId": "NCT05054166",
    "briefTitle": "Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study",
    "officialTitle": "Efficacy of Everolimus-containing Chemotherapy in HER2 Negative Metastatic Breast Cancer Patients With PI3K/AKT/mTOR Mutations: A Retrospective Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, PI3K/AKT/mTOR Pathway Mutation, Everolimus",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with HER2- metastatic breast cancer\n2. Patients with PI3K/AKT/mTOR mutation\n\nExclusion Criteria:\n\n1. Patients treated with endocrinotherapy and everolimus.\n2. The efficacy evaluation could not be available.",
    "sex": "FEMALE",
    "minimumAge": "29 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}